Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00417430 | Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies | PHASE2 | COMPLETED | 20 | — | — | Sep 1, 2004 | Dec 1, 2006 | Sep 22, 2009 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| ICI 182,780 (Faslodex) | DRUG | - |
Inclusion Criteria: * Premenopausal women with SLE * Without life-threatening manifestations * With regular menstrual cyles not on hormones of any kind Exclusion Criteria: For any of the following: * Increase of SLEDAI greater than 12 * If life-threatening manifestations occur * If menstruation ...